$1.75 Earnings Per Share Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter

Equities analysts expect that Zimmer Biomet Holdings, Inc. (NYSE:ZBH) will post earnings per share (EPS) of $1.75 for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Zimmer Biomet Holdings’ earnings, with the lowest EPS estimate coming in at $1.72 and the highest estimate coming in at $1.79. Zimmer Biomet Holdings posted earnings per share of $1.79 in the same quarter last year, which suggests a negative year over year growth rate of 2.2%. The company is scheduled to issue its next earnings results before the market opens on Wednesday, November 1st.

On average, analysts expect that Zimmer Biomet Holdings will report full year earnings of $8.24 per share for the current year, with EPS estimates ranging from $8.20 to $8.27. For the next year, analysts expect that the firm will report earnings of $8.80 per share, with EPS estimates ranging from $8.55 to $9.23. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Zimmer Biomet Holdings.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period last year, the company earned $2.02 EPS.

ZBH has been the subject of several research reports. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Morgan Stanley upped their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and a consensus price target of $136.55.

In other news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.07% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of ZBH. Bronfman E.L. Rothschild L.P. grew its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after buying an additional 33 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares during the period. IHT Wealth Management LLC boosted its holdings in shares of Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the period. Finally, BB&T Investment Services Inc. bought a new stake in Zimmer Biomet Holdings in the 2nd quarter valued at $144,000. 85.22% of the stock is owned by institutional investors.

Shares of Zimmer Biomet Holdings (NYSE ZBH) traded down 0.07% during trading on Monday, reaching $119.62. The company had a trading volume of 157,027 shares. The stock’s 50-day moving average price is $116.07 and its 200-day moving average price is $120.38. Zimmer Biomet Holdings has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a market capitalization of $24.19 billion, a PE ratio of 34.07 and a beta of 1.19.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.

ILLEGAL ACTIVITY NOTICE: “$1.75 Earnings Per Share Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/16/1-75-earnings-per-share-expected-for-zimmer-biomet-holdings-inc-zbh-this-quarter.html.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet Holdings (ZBH)

For more

On average, analysts expect that Zimmer Biomet Holdings will report full year earnings of $8.24 per share for the current year, with EPS estimates ranging from $8.20 to $8.27. For the next year, analysts expect that the firm will report earnings of $8.80 per share, with EPS estimates ranging from $8.55 to $9.23. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Zimmer Biomet Holdings.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period last year, the company earned $2.02 EPS.

ZBH has been the subject of several research reports. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Morgan Stanley upped their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and a consensus price target of $136.55.

In other news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.07% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of ZBH. Bronfman E.L. Rothschild L.P. grew its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after buying an additional 33 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares during the period. IHT Wealth Management LLC boosted its holdings in shares of Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the period. Finally, BB&T Investment Services Inc. bought a new stake in Zimmer Biomet Holdings in the 2nd quarter valued at $144,000. 85.22% of the stock is owned by institutional investors.

Shares of Zimmer Biomet Holdings (NYSE ZBH) traded down 0.07% during trading on Monday, reaching $119.62. The company had a trading volume of 157,027 shares. The stock’s 50-day moving average price is $116.07 and its 200-day moving average price is $120.38. Zimmer Biomet Holdings has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a market capitalization of $24.19 billion, a PE ratio of 34.07 and a beta of 1.19.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.

ILLEGAL ACTIVITY NOTICE: “$1.75 Earnings Per Share Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/16/1-75-earnings-per-share-expected-for-zimmer-biomet-holdings-inc-zbh-this-quarter.html.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet Holdings (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply